08:37:25 EST Wed 18 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:CVKD - CADRENAL THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CVKD - Q0.11.67·1.840.81.888.91224    12.50  0.816308:14:23Oct 0715 min RT 2¢

Recent Trades - Last 10 of 24
Time ETExPriceChangeVolume
08:14:23Q1.8216-0.05841
08:08:40Q1.84-0.04200
08:08:40Q1.8104-0.0696200
08:08:19Q1.84-0.043
08:07:47Q1.82-0.061
08:07:47Q1.82-0.061
08:07:47Q1.84-0.041,013
08:07:47Q1.84-0.04285
08:07:47Q1.84-0.04700
07:53:09Q1.84-0.0415

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-07 07:00U:CVKDNews ReleaseCadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
2026-09-21 16:30U:CVKDNews ReleaseCadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
2026-09-03 08:00U:CVKDNews ReleaseCadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
2026-08-31 08:00U:CVKDNews ReleaseCadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
2026-08-13 16:15U:CVKDNews ReleaseCadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
2026-08-03 08:30U:CVKDNews ReleaseCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation
2026-07-21 08:00U:CVKDNews ReleaseCadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
2026-07-13 09:00U:CVKDNews ReleaseCadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
2026-06-30 20:01U:CVKDNews ReleaseCadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-06-24 08:00U:CVKDNews ReleaseCadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
2026-06-18 09:00U:CVKDNews ReleaseCadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
2026-06-15 08:30U:CVKDNews ReleaseCadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
2026-06-03 09:00U:CVKDNews ReleaseCadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
2026-05-19 16:30U:CVKDNews ReleaseCadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-07 08:30U:CVKDNews ReleaseCadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
2026-04-30 08:30U:CVKDNews ReleaseCadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
2026-03-31 08:45U:CVKDNews ReleaseCadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
2026-03-12 08:00U:CVKDNews ReleaseCadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
2026-03-02 08:00U:CVKDNews ReleaseCadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
2026-02-24 08:30U:CVKDNews ReleaseCadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement